Literature DB >> 26984416

What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?

Joyce F Liu1, Ursula A Matulonis2.   

Abstract

Poly-ADP-ribose polymerase (PARP) inhibitors have been one of the most exciting developments in the treatment of ovarian cancer in recent years. Demonstration of anti-cancer activity has led to the European Medicines Agency (EMA) approval of the PARP inhibitor (PARPi) olaparib as maintenance therapy in women with BRCA-mutated (BRCAm) ovarian cancer with platinum-sensitive recurrence following response to platinum therapy and the US Food and Drug Administration (US FDA) approval of olaparib in relapsed germline BRCA-mutated (gBRCAm) ovarian cancer in women who have received at least three prior chemotherapy treatments, both occurring in 2014. Additional trials are underway or awaiting final analysis with olaparib, other PARPis, and PARPi combinations to further elucidate the activity of these drugs in various clinical settings. This review will focus on the current clinical experience and ongoing trials with PARPis in ovarian cancer.

Entities:  

Keywords:  Niraparib; Olaparib; Ovarian cancer; PARP inhibitors; Rucaparib; Veliparib

Mesh：

Substances：

Year:  2016        PMID： 26984416     DOI： 10.1007/s11912-016-0515-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  38 in total

1.  A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Robert L Coleman; Michael W Sill; Katherine Bell-McGuinn; Carol Aghajanian; Heidi J Gray; Krishnansu S Tewari; Steven C Rubin; Thomas J Rutherford; John K Chan; Alice Chen; Elizabeth M Swisher
Journal:  Gynecol Oncol       Date:  2015-03-24       Impact factor: 5.482

2.  Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.

Authors:  Panagiotis A Konstantinopoulos; Andrew J Wilson; Jeanette Saskowski; Erica Wass; Dineo Khabele
Journal:  Gynecol Oncol       Date:  2014-03-11       Impact factor: 5.482

3.  Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.

Authors:  Stan B Kaye; Jan Lubinski; Ursula Matulonis; Joo Ern Ang; Charlie Gourley; Beth Y Karlan; Amit Amnon; Katherine M Bell-McGuinn; Lee-May Chen; Michael Friedlander; Tamar Safra; Ignace Vergote; Mark Wickens; Elizabeth S Lowe; James Carmichael; Bella Kaufman
Journal:  J Clin Oncol       Date:  2011-12-27       Impact factor: 44.544

4.  VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.

Authors:  Jaeyoung J Lim; Kun Yang; Barbie Taylor-Harding; W Ruprecht Wiedemeyer; Ronald J Buckanovich
Journal:  Neoplasia       Date:  2014-04       Impact factor: 5.715

5.  Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

Authors:  Panagiotis A Konstantinopoulos; Dimitrios Spentzos; Beth Y Karlan; Toshiyasu Taniguchi; Elena Fountzilas; Nancy Francoeur; Douglas A Levine; Stephen A Cannistra
Journal:  J Clin Oncol       Date:  2010-06-14       Impact factor: 44.544

6.  Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.

Authors:  Tatiana Popova; Elodie Manié; Guillaume Rieunier; Virginie Caux-Moncoutier; Carole Tirapo; Thierry Dubois; Olivier Delattre; Brigitte Sigal-Zafrani; Marc Bollet; Michel Longy; Claude Houdayer; Xavier Sastre-Garau; Anne Vincent-Salomon; Dominique Stoppa-Lyonnet; Marc-Henri Stern
Journal:  Cancer Res       Date:  2012-08-29       Impact factor: 12.701

7.  CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.

Authors:  Tomoe Higuchi; Dallas B Flies; Nicole A Marjon; Gina Mantia-Smaldone; Lukas Ronner; Phyllis A Gimotty; Sarah F Adams
Journal:  Cancer Immunol Res       Date:  2015-07-02       Impact factor: 11.151

8.  Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.

Authors:  Ranjit S Bindra; Shannon L Gibson; Alice Meng; Ulrica Westermark; Maria Jasin; Andrew J Pierce; Robert G Bristow; Marie K Classon; Peter M Glazer
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

9.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.

Authors:  V Abkevich; K M Timms; B T Hennessy; J Potter; M S Carey; L A Meyer; K Smith-McCune; R Broaddus; K H Lu; J Chen; T V Tran; D Williams; D Iliev; S Jammulapati; L M FitzGerald; T Krivak; J A DeLoia; A Gutin; G B Mills; J S Lanchbury
Journal:  Br J Cancer       Date:  2012-10-09       Impact factor: 7.640

10.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Authors:  Junko Murai; Shar-yin N Huang; Benu Brata Das; Amelie Renaud; Yiping Zhang; James H Doroshow; Jiuping Ji; Shunichi Takeda; Yves Pommier
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 13.312
View more
  9 in total

Review 1.  Excessive Reactive Oxygen Species and Exotic DNA Lesions as an Exploitable Liability.

Authors:  Safnas F AbdulSalam; Fathima Shazna Thowfeik; Edward J Merino
Journal:  Biochemistry       Date:  2016-09-13       Impact factor: 3.162

Review 2.  PARP inhibitors in ovarian cancer: evidence, experience and clinical potential.

Authors:  Tarra Evans; Ursula Matulonis
Journal:  Ther Adv Med Oncol       Date:  2017-02-03       Impact factor: 8.168

Review 3.  Adaptive mechanisms of resistance to anti-neoplastic agents.

Authors:  Bibiana I Ferreira; Maria K Lie; Agnete S T Engelsen; Susana Machado; Wolfgang Link; James B Lorens
Journal:  Medchemcomm       Date:  2016-10-21       Impact factor: 3.597

Review 4.  Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment.

Authors:  Veronica Rojas; Kim M Hirshfield; Shridar Ganesan; Lorna Rodriguez-Rodriguez
Journal:  Int J Mol Sci       Date:  2016-12-15       Impact factor: 5.923

Review 5.  Reverse the Resistance to PARP Inhibitors.

Authors:  Yevgeniy Kim; Aleksei Kim; Ainur Sharip; Aigul Sharip; Juhong Jiang; Qing Yang; Yingqiu Xie
Journal:  Int J Biol Sci       Date:  2017-02-17       Impact factor: 6.580

Review 6.  Potential clinical utility of liquid biopsies in ovarian cancer.

Authors:  Jie Wei Zhu; Parsa Charkhchi; Mohammad R Akbari
Journal:  Mol Cancer       Date:  2022-05-11       Impact factor: 41.444

Review 7.  PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.

Authors:  Mekonnen Sisay; Dumessa Edessa
Journal:  Gynecol Oncol Res Pract       Date:  2017-11-29

8.  Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.

Authors:  Florian Engert; Michal Kovac; Daniel Baumhoer; Michaela Nathrath; Simone Fulda
Journal:  Oncotarget       Date:  2017-07-25

9.  An optimized BRCA1/2 next-generation sequencing for different clinical sample types.

Authors:  Yoonjung Kim; Chi Heum Cho; Jung Sook Ha; Do Hoon Kim; Sun Young Kwon; Seoung Chul Oh; Kyung A Lee
Journal:  J Gynecol Oncol       Date:  2019-08-06       Impact factor: 4.401
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.